胃と腸40巻10号

2005年09月発行

今月の主題 難治性潰瘍性大腸炎―診断と治療の新知見 主題

難治性潰瘍性大腸炎の病態と治療方針

著者： 桜庭篤¹ 日比紀文¹

所属機関： ¹慶應義塾大学医学部内科学

ページ範囲：P.1347 - P.1351

要旨　潰瘍性大腸炎の大部分の症例は5-アミノサリチル酸製剤やステロイド製剤により緩解導入，緩解維持が可能であるが，これらの通常の治療法では緩解導入が困難な症例，あるいは緩解導入後にステロイド製剤の漸減により再燃する症例などの，いわゆる難治例も存在するのが現状である．難治性潰瘍性大腸炎の代表として，ステロイド抵抗性，ステロイド依存性の症例が挙げられるが，本稿では主に実際の臨床に即した難治性潰瘍性大腸炎の病態と治療について，研究班の治療指針に基づいて概説する．

参考文献

1）棟方昭博．潰瘍性大腸炎の難治例の定義に関する研究．厚生科学研究費補助金特定疾患対策研究事業―難治性炎症性腸管障害に関する調査研究班（班長: 日比紀文），平成14 年度研究報告書，pp 11-13, 2003

2）Leonard-Jones JE. An assesment of prednisone, salazopyrine, and topical hydrocortisone hemisiccinate used as outpatient treatment for ulcerative colitis. Gut1 : 217-222, 1960

3）Leonard-Jones JE. Towards optimal use of corticosteroids in ulcerative colitis and Crohn's disease. Gut 24 :177-181, 1983

4）Powell-Tuck J. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scand J Gastroenterol 13 : 833-837, 1978

5）Lindgren SC, Flood LM, Kilander AF, et al. Early predicotors of glucocorticosteroid treatment failure in severe and moderately severe attacks of ulcerative colitis. Eur J Gastroenterol Hepatol 10 : 831-835, 1998

6）Gelbmann CM. Prediction of treatment refractoriness in ulcerative colitis and Crohn's disease―do we have reliable markers? Inflamm Bowel Dis 6 : 123-131, 2000

7）Roozendaal C, Kallenberg CG. Are antinuteutrophil cytoplasmic antibodies（ANCA）clinically useful in inflammatory bowel disease（IBD）? Clin Exp Immunol116 : 206-213, 1999

8）Tanaka M, Saito H, Kusumi T, et al. Biopsy pathology predicts patients with ulcerative colitis subsequently requiring srgery. Scand J Gastroenterol 37 : 200-205, 2002

9）Schottelius A, Wedel S, Weltrich R, et al. Higher expression of glucocorticosteroid receptor in peripheral mononuclear cells in inflammatory bowel disease. Am J Gastroenterol 95 : 1994-1999, 2000

10）Hearing SD, Norman M, Probert CS, et al. Predicting therapeutic outcome in severe ulcerative colitis by measuring in vitro steroid sensitivity of proliferating peripheral blood lymphocytes. Gut 45 : 382-388, 1999

11）Honda M, Orii F, Ayabe T, et al. Expression of glucocorticosteroid receptor β in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 118 : 859-866, 2000

12）Bantel H, Domschke W, Schulze-Osthoff K. Molecular mechanisms of glucocorticoid resistance. Gastroenterology 119 : 1178-1179, 2000

13）Lichtiger S, Present DH. Preliminary report : cyclosporine in the treatment of severe ulcerative colitis. Lancet 336 : 16-19, 1990

14）Shimoyama T, Sawada K, Hiwatashi N, et al. Safety and efficacy of granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis : a multicenter study. J Clin Apheresis 16 : 1-9, 2001

15）Sawada K, Muto T, Shimoyama T, et al. Multicenterrandomized controlled trial for the treatment of ulcerative colitis with a leukocytapheresis column. Curr Pharm Des 9 : 307-321, 2003

16）Naganuma M, Funakoshi S, Sakuraba A, et al. Granulocytapheresis is useful as an alterative therapy in patients with steroid-refractory or-dependent ulcerative colitis. Inflamm Bowel Dis 10 : 251-257, 2004

17）Truelove SC, Witts LJ. Cortisone and corticotrophin in ulcerative colitis. Br Med J 1 : 387-394, 1959

18）Fraser AG, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease : a 30 year review. Gut 50 : 485-489, 2002